Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL33328, USA.
Asian J Androl. 2020 Sep-Oct;22(5):441-446. doi: 10.4103/aja.aja_139_19.
Androgen deprivation therapy (ADT) is the mainstay for the treatment of advanced prostate cancer. Since the clinical evolution from surgical orchiectomy, we have typically used ADT and orchiectomy to be synonymous terms for castration. The goal of this study is to determine if, in contemporary medical practice, surgical and chemical castration provide for similar levels of diminishment of total and free testosterone. Further, what approaches should be used to most accurately measure testosterone levels in men with advanced prostate cancer and what cutoff values, for example for total testosterone 50 ng dl or 20 ng dl, should be utilized. Studies available in the literature have been analyzed and compiled to address these questions. Finally, evidence is provided that free testosterone, the biologically active component, should be utilized to provide clinically relevant state of castration.
雄激素剥夺疗法(ADT)是治疗晚期前列腺癌的主要方法。自手术去势以来,我们通常将 ADT 和去势术视为同义词,用于指代阉割。本研究旨在确定在当代医疗实践中,手术去势和化学去势是否能使总睾酮和游离睾酮水平降低到相似程度。此外,对于晚期前列腺癌患者,应该采用哪些方法来最准确地测量睾酮水平,以及应该采用什么样的截断值,例如总睾酮 50ng/dl 或 20ng/dl。对文献中的现有研究进行了分析和汇编,以回答这些问题。最后,有证据表明,应该使用生物活性成分游离睾酮来提供具有临床相关性的去势状态。